United States Últimas notícias

Ryanair Holdings plc (NASDAQ:RYAAY) reported its finalized, record-breaking financial results for the fiscal year ended March 31, 2026 (FY26), highlighting explosive bottom-line performance, strategic fuel defenses, and significant corporate restructuring.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) announced positive chemistry, manufacturing, and controls (CMC) data supporting the late-stage development of its lead antimicrobial candidate, Nu-3.

C3is (NASDAQ:CISS) announced its financial and operational results for the first quarter ended March 31, 2026, delivering substantial bottom-line expansion and enhanced operating leverage.

INNEOVA Holdings (NASDAQ:INEO) announced its audited financial results for the fiscal year ended December 31, 2025, charting a period of transition and operational realignment.

MIAX CEO Thomas Gallagher joins Bloomberg Open Interest to explain why the exchange is betting big on retail futures trading, how mega IPOs like SpaceX could reshape options markets, and why Miami is emerging as "Wall Street South." The conversation also covers Bloomberg's new equity index futures launch and the next phase of MIAX's expansion strategy.

The amount of inflation priced into 10-year Treasury yields is a little hard to square with what the market is saying about price rises in the near term. Either inflation is going to be high for a long time, and this is something that has changed in the past week or two, or 10-year yields have gone a little too far. Yelena Shulyatyeva, Senior US Economist at The Conference Board, discusses inflation expectations and what happens if oil prices rise higher, for longer.

A new era of elevated borrowing costs is potentially underway as war-driven inflation angst intensifies in the US bond market, sending 30-year yields toward a two-decade high above 5%. Guneet Dhingra, Head of US Rates Strategy at BNP Paribas, discusses the recent yield surge and why 5% may become the new 4%.

Design Therapeutics (NASDAQ:DSGN) announced positive biomarker and clinical findings from its ongoing Phase 1/2 RESTORE-FA clinical trial evaluating DT-216P2 in individuals with Friedreich ataxia (FA).

On this episode of Stock Movers with Alexis Christoforous: - NextEra Energy (NEE) agreed to pay about $67 billion in stock for Dominion Energy (D) in the biggest power acquisition ever, creating a giant utility extending from Florida to the data centers clustered in Virginia. The deal would give NextEra a swathe of electricity assets stretching across Virginia and the Carolinas. - Ryanair (RYAAY) gains as it delivered a decent end to the year, but flagged impact ahead from rising costs. The airline said unit costs for 2027 could increase by a mid-single digit percentage, with concerns over current unhedged jet fuel prices, and also impact from higher crew and aircraft maintenance costs. - Regeneron Pharmaceuticals (REGN) shares drop after the drugmaker's phase 3 data for fianlimab in metastatic melanoma fell short of expectations. Citi downgraded its rating on the stock following the "disappointing" trial update.

Brady Corporation (NYSE:BRC) reported its financial results for the fiscal 2026 third quarter ended April 30, 2026, delivering substantial top-line acceleration and record-setting profitability metrics.

AstraZeneca (NASDAQ:AZN) announced that the U.S. Food and Drug Administration (FDA) has approved BAXFENDY™ (baxdrostat) for the treatment of hypertension in adults.

Ramaco CEO Randall Atkins joined Bloomberg Open Interest to explain why China's steel dumping has hurt coal markets, why the company is betting big on rare earth minerals, and why processing, and not necessarily mining, is the toughest hurdle in building a US rare earth supply chain that's independent of China.